Cyanosis From PH or Congenital Heart Disease Responds Well to IV Ferrous Carboxymaltose

Cyanosis From PH or Congenital Heart Disease Responds Well to IV Ferrous Carboxymaltose

After iron supplementation, patients with cyanosis experienced significant improvements in hemoglobin concentration, hematocrit, mean corpuscular volume, ferritin, and transferrin saturation.

Oxygen Therapy Affects Health-Related QoL in Pulmonary Hypertension

Oxygen Therapy Affects Health-Related QoL in Pulmonary Hypertension

Strong relationships were observed between health-related quality-of-life scores and factors such as breathlessness, fatigue, depression, anxiety, and sleep in pulmonary hypertension.

Age-Obesity Interaction in Pulmonary Arterial Hypertension

Age-Obesity Interaction in Pulmonary Arterial Hypertension

The interaction of age and obesity with respect to survival in pulmonary arterial hypertension showed an increased risk for mortality in young adults who were morbidly obese.

PAH in Systemic Sclerosis Increases Risk for Early Mortality

PAH in Systemic Sclerosis Increases Risk for Early Mortality

The majority of deaths in patients with systemic sclerosis-associated pulmonary arterial hypertension occurred within 4 years of diagnosis.

CTEPH Increases Risk for Sleep Disordered Breathing

CTEPH Increases Risk for Sleep Disordered Breathing

Precapillary pulmonary hypertension and obstructive sleep apnea may be causative factors for central sleep apnea and pulmonary hypertension, respectively.

Sildenafil, Bosentan Combination vs Sildenafil Monotherapy in SSc-Associated PAH

Sildenafil, Bosentan Combination vs Sildenafil Monotherapy in SSc-Associated PAH

There was no significant difference in efficacy between sildenafil and bosentan initial combination therapy and sildenafil monotherapy in patients with systemic sclerosis-related pulmonary arterial hypertension.

Clinical Trials in PAH: Interpreting Risk Reduction With Caution

Clinical Trials in PAH: Interpreting Risk Reduction With Caution

Researchers raise issues regarding interpretation of clinical trial results in the field of pulmonary arterial hypertension.

PAH Pulmonary Hemodynamics Improved With Optimized Iloprost Delivery

PAH Pulmonary Hemodynamics Improved With Optimized Iloprost Delivery

Researchers modified the inhalation technique of iloprost in a patient with pulmonary arterial hypertension by attaching a nasal cannula to the inhalator's inlet port, shortening the administration duration.

Improved Pulmonary Arterial Hypertension Risk Prediction Tools Needed

Improved Pulmonary Arterial Hypertension Risk Prediction Tools Needed

The use of a risk calculator aimed at achieving a low-risk profile in PAH trials is discussed.

Arrhythmia Associated With Higher Mortality in Congenitial Heart Disease-Related PAH

Arrhythmia Associated With Higher Mortality in Congenitial Heart Disease-Related PAH

Arrhythmia was a significant predictor of mortality in adult patients with congenital heart disease and pulmonary arterial hypertension.

Right Ventricular Stroke Work Effective Biomarker in Pediatric PAH

Right Ventricular Stroke Work Effective Biomarker in Pediatric PAH

Clinical worsening in pediatric pulmonary arterial hypertension may be predicted using right ventricular stroke work indexed by ejection fraction.

Composite Echo Score Predicts PH in Interstitial Lung Disease

Composite Echo Score Predicts PH in Interstitial Lung Disease

The variables for the stepwise echocardiographic score included right ventricular systolic pressure, early pulmonary regurgitation gradient, right atrial area size, tricuspid regurgitation velocity, left ventricle eccentricity index, and right ventricle fractional area change.

Brain Natriuretic Peptide Shows Promise as Biomarker in Group 1 PAH

Brain Natriuretic Peptide Shows Promise as Biomarker in Group 1 PAH

There was a significant relationship between brain natriuretic peptide levels and mortality in patients with group 1 pulmonary arterial hypertension.

Poor Subpleural Perfusion May Predict Balloon Pulmonary Angioplasty Failure

Poor Subpleural Perfusion May Predict Balloon Pulmonary Angioplasty Failure

Poor subpleural perfusion in patients with nonoperable chronic thromboembolic pulmonary hypertension may predict balloon pulmonary angioplasty failure.

Metformin May Benefit Pulmonary Hypertension Associated With HFpEF, But Not PAH

Metformin May Benefit Pulmonary Hypertension Associated With HFpEF, But Not PAH

Although metformin prevented the development of PAH in hypoxia and monocrotalinerat models and reversed PAH in SU5416/hypoxia rats, it failed to reverse pulmonary pressures and vascular remodeling in mice with SU5416/hypoxia-induced PAH.

PAH-Associated Connective Tissue Diseases: A Case for Separating SSc, SLE

PAH-Associated Connective Tissue Diseases: A Case for Separating SSc, SLE

Recent evidence suggests that systemic sclerosis and systemic lupus erythematosus in pulmonary arterial hypertension should be considered separate diseases.

Pulmonary Hypertension Has Adverse Effect on Post-Lung Transplant Survival

Pulmonary Hypertension Has Adverse Effect on Post-Lung Transplant Survival

The 1-year survival rate after lung transplantation in patients with a mean pulmonary arterial pressure ≥25 mm Hg was lower than the survival rate of those with a mean pulmonary arterial pressure <25 mm Hg.

PAH-SYMPACT®: A Reliable Instrument for PAH Symptom Assessment

PAH-SYMPACT®: A Reliable Instrument for PAH Symptom Assessment

The Pulmonary Arterial Hypertension-Symptoms and Impact questionnaire has good psychometric properties and can be administered in clinical practice.

Egg-and-Banana Sign Has High Specificity for Pulmonary Hypertension Diagnosis

Egg-and-Banana Sign Has High Specificity for Pulmonary Hypertension Diagnosis

The "egg-and-banana" sign is a valid computed tomography marker of pulmonary hypertension.

Oral Anticoagulant Effective in Recurrent VTE Prevention in Cancer Patients

Oral Anticoagulant Effective in Recurrent VTE Prevention in Cancer Patients

At the end of 6 months, the rate of VTE recurrence was 4% among rivaroxaban patients vs 11% in the dalteparin arm (hazard ratio [HR] 0.43, 95% CI: 0.19 to 0.99).

Serum Chloride Linked With Survival in Pulmonary Arterial Hypertension

Serum Chloride Linked With Survival in Pulmonary Arterial Hypertension

Serum chloride was a strong and independent predictor of mortality at 6 months after a pulmonary arterial hypertension diagnosis.

YEARS Criteria in Pulmonary Embolism Evaluation May Reduce Need for Imaging

YEARS Criteria in Pulmonary Embolism Evaluation May Reduce Need for Imaging

D-dimer test adjustment based on pretest probability results may be a safe option to reduce the need for imaging during evaluation for pulmonary embolism.

Copeptin May Serve as Prognostic Biomarker for Pulmonary Embolism

Copeptin May Serve as Prognostic Biomarker for Pulmonary Embolism

Copeptin may be useful for identifying normotensive patients with pulmonary embolism who have a higher risk for an adverse outcome.

Survival Rates With Parenteral Prostanoids in Pulmonary Arterial Hypertension

Survival Rates With Parenteral Prostanoids in Pulmonary Arterial Hypertension

In patients with pulmonary arterial hypertension who were treated with a parenteral prostanoid, survival was linked with the number of guideline-recommended lower-risk and higher-risk criteria attained.

Pulmonary Arterial Hypertension Prognosis Linked to Walking Distance

Pulmonary Arterial Hypertension Prognosis Linked to Walking Distance

Walking a distance of >400 meters in the 6-minute walk test was associated with a reduced risk for pulmonary arterial hypertension-related death or hospitalization.

Opsumit sNDA Submitted for Chronic Thromboembolic Pulmonary Hypertension

Opsumit sNDA Submitted for Chronic Thromboembolic Pulmonary Hypertension

The sNDA is accompanied by results from the MERIT-1 trial, a Phase 2 randomized, placebo-controlled, double-blind study which assessed the efficacy, safety and tolerability of macitentan 10mg in 80 patients with inoperable CTEPH.

Stem Cell Therapy for RV Failure in PAH: Overview and Clinician Interview

Stem Cell Therapy for RV Failure in PAH: Overview and Clinician Interview

Stem cell therapy targeting right ventricular failure may help improve pulmonary circulation in pulmonary arterial hypertension.

Predictive Value of Idiopathic PAH Risk Assessment Using Comorbidities, Age

Predictive Value of Idiopathic PAH Risk Assessment Using Comorbidities, Age

Ischemic heart disease and kidney dysfunction were identified as 2 comorbidities that may affect outcomes in idiopathic pulmonary arterial hypertension.

PAAT May Detect Pulmonary Vascular Disease in Preterm Infants

PAAT May Detect Pulmonary Vascular Disease in Preterm Infants

Regardless of neonatal lung disease status, infants born before 29 weeks' gestation demonstrated abnormal pulmonary artery acceleration time at 1-year corrected age.

Benefits of Targeted Pharmacologic Therapy in PAH and Distal CTEPH

Benefits of Targeted Pharmacologic Therapy in PAH and Distal CTEPH

In patients with pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension, targeted pharmacologic treatment was associated with an increase in achieved therapeutic goals.

Perioperative Risk Assessment in a Patient With COPD

Perioperative Risk Assessment in a Patient With COPD

A 64-year-old man with chronic obstructive pulmonary disease, diabetes, chronic kidney disease, and morbid obesity seeks preoperative approval for femoral popliteal bypass surgery.

Pulmonary Arterial Hypertension Outcomes With Atrial Arrhythmia

Pulmonary Arterial Hypertension Outcomes With Atrial Arrhythmia

Increased right atrial and pulmonary wedge pressures and increased thyroid disease prevalence were associated with atrial arrhythmia development in idiopathic or systemic sclerosis-related pulmonary arterial hypertension.

Oral Treprostinil Dosing Characteristics in Pulmonary Arterial Hypertension

Oral Treprostinil Dosing Characteristics in Pulmonary Arterial Hypertension

Prescribers tend to favor a frequency of 3 times per day for oral treprostinil dosing in patients with pulmonary arterial hypertension.

Pulmonary Hypertension Outcomes Predicted by NT-proBNP

Pulmonary Hypertension Outcomes Predicted by NT-proBNP

N-terminal-pro brain natriuretic peptide may be a useful biomarker for both mortality and respiratory exacerbations in pediatric patients with pulmonary hypertension.

Pulmonary Hypertension Mortality Following Cardiac Catheterization

Pulmonary Hypertension Mortality Following Cardiac Catheterization

Patients with pulmonary hypertension have a high risk for adverse events during and following cardiac catheterization, but high case volume may help ameliorate this risk.

Pulmonary Hypertension With HFpEF Mortality Predicted by Hemodynamic Markers

Pulmonary Hypertension With HFpEF Mortality Predicted by Hemodynamic Markers

The hemodynamic parameters predict mortality and cardiac hospitalization in patients with heart failure with preserved ejection fraction.

Middle-Aged Woman With Progressive Exertional Dyspnea

Middle-Aged Woman With Progressive Exertional Dyspnea

A 57-year-old woman has been experiencing progressive exertional dyspnea during the past 6 months as well as a near syncopal episode while attempting to catch a taxi.

A 32-Year-Old Pregnant Woman Presents With Worsening Dyspnea

A 32-Year-Old Pregnant Woman Presents With Worsening Dyspnea

Several months after being diagnosed with pulmonary arterial hypertension, a 32-year-old pregnant woman presents with worsening dyspnea.

PDE-5 Inhibitor Prescribing Trends in US Veterans With Pulmonary Hypertension

PDE-5 Inhibitor Prescribing Trends in US Veterans With Pulmonary Hypertension

Nearly two-thirds of phosphodiesterase-5 inhibitor prescriptions for US veterans are inconsistent with pulmonary hypertension guidelines.

Claims-Based Algorithms for Pulmonary Arterial Hypertension Developed

Claims-Based Algorithms for Pulmonary Arterial Hypertension Developed

Patients with pulmonary arterial hypertension may be better identified through a claims-based algorithm that includes ICD-9-CM codes, specific pulmonary arterial hypertension medications, echocardiography, and right heart catheterization.

Comparing Prognosis of Pulmonary Arterial Hypertension in Men and Women

Comparing Prognosis of Pulmonary Arterial Hypertension in Men and Women

Women with pulmonary arterial hypertension experienced better long-term prognosis than men with PAH.

Supraventricular Arrhythmia in PAH Predicted by Right Atrium Enlargement

Supraventricular Arrhythmia in PAH Predicted by Right Atrium Enlargement

Enlargement of the right atrium is associated with an increased risk for supraventricular arrhythmias in PAH.

Varicose Veins May Increase Risk for Pulmonary Embolism

Varicose Veins May Increase Risk for Pulmonary Embolism

Varicose veins may increase the risk for pulmonary embolism and peripheral artery disease.

Idiopathic Pulmonary Arterial Hypertension and Risk for Cardiac Events

Idiopathic Pulmonary Arterial Hypertension and Risk for Cardiac Events

Peak circulatory power offers greater value than peak oxygen uptake and ventilation in predicting cardiac events in patients with idiopathic PAH.

Hypoxemia in Idiopathic Pulmonary Arterial Hypertension Linked to Increased Mortality

Hypoxemia in Idiopathic Pulmonary Arterial Hypertension Linked to Increased Mortality

Hypoxemia in individuals with idiopathic PAH is associated with increased mortality risk.

Pulmonary Embolism With Low Mortality Risk May Be Managed in Outpatient Setting

Pulmonary Embolism With Low Mortality Risk May Be Managed in Outpatient Setting

Observation in the emergency department followed by outpatient management with anticoagulation may be appropriate treatment for some patients with low-risk pulmonary embolism.

Safety and Validity of Pulmonary Embolism Rule-Out Criteria Evaluated

Safety and Validity of Pulmonary Embolism Rule-Out Criteria Evaluated

In patients at very low risk for pulmonary embolism, the pulmonary embolism rule-out criteria was noninferior to the conventional strategy of identifying thromboembolic events.

Performing Two 6MWTs in Pulmonary Hypertension Minimizes "Learning Effect"

Performing Two 6MWTs in Pulmonary Hypertension Minimizes "Learning Effect"

Patients with suspected PH should undergo two 6MWTs to improve the accuracy of exercise capacity measurements.

Prognostic Value of 6MWT in Pulmonary Arterial Hypertension

Prognostic Value of 6MWT in Pulmonary Arterial Hypertension

The 6-minute walk test had prognostic value with respect to mortality in a population of patients with pulmonary arterial hypertension.

Pulmonary Hypertension Treatments Compared for Safety, Adverse Events

Pulmonary Hypertension Treatments Compared for Safety, Adverse Events

Individuals treated with riociguat for pulmonary hypertension may have a greater risk for gastrointestinal disorders compared with tadalafil and sildenafil.

Pulmonary Arterial Hypertension: Improving Survival Rates

Pulmonary Arterial Hypertension: Improving Survival Rates

Brain natriuretic peptide levels may accurately predict 5-year survival rates in patients with pulmonary arterial hypertension.

Validity of Pulmonary Embolism Prediction Scores in Pregnant, Postpartum Women

Validity of Pulmonary Embolism Prediction Scores in Pregnant, Postpartum Women

Although the Wells and revised Geneva scores are used in the general population to predict pulmonary embolism, researchers found they were not reliable in pregnant and postpartum women.

Monitoring Pulmonary Hemodynamic Changes in CTEPH With 6-Minute Walk Test

Monitoring Pulmonary Hemodynamic Changes in CTEPH With 6-Minute Walk Test

Pulmonary hemodynamic changes in chronic thromboembolic pulmonary hypertension may be monitored via the 6-minute walk test.

Improving Prognosis in Idiopathic Pulmonary Fibrosis-Associated Pulmonary Hypertension

Improving Prognosis in Idiopathic Pulmonary Fibrosis-Associated Pulmonary Hypertension

Bosentan may benefit a subset of patients with idiopathic pulmonary fibrosis-associated pulmonary hypertension.

New Trial to Assess Dabigatran in Intermediate-Risk Pulmonary Embolism

New Trial to Assess Dabigatran in Intermediate-Risk Pulmonary Embolism

A clinical trial is underway to assess the safety and efficacy of dabigatran in intermediate-risk pulmonary embolism after completing 72 hours of heparin therapy.

REVEAL Risk Score for Long-Term Outcomes in PAH

REVEAL Risk Score for Long-Term Outcomes in PAH

The REVEAL risk score gives significant predictive value for long-term survival and changes in mortality risk in patients with PAH.

PAH: Implantable Treprostinil Delivery System Is Promising

PAH: Implantable Treprostinil Delivery System Is Promising

A fully implantable programmable intravascular delivery system using treprostinil was found to be highly stable in patients with PAH.

Pulmonary Hypertension Predicts Heart Transplant Outcomes Better Than Age

Pulmonary Hypertension Predicts Heart Transplant Outcomes Better Than Age

Pulmonary hypertension may be more important than age in predicting heart transplant outcomes.

Pulmonary Arterial Hypertension Survival May Be Linked to Kidney Function

Pulmonary Arterial Hypertension Survival May Be Linked to Kidney Function

A study evaluated whether changes in estimated glomerular filtration rate were predictive of mortality in patients with pulmonary arterial hypertension.

Pulmonary Emboli in Pediatric Patients: Clinical Predictors Identified

Pulmonary Emboli in Pediatric Patients: Clinical Predictors Identified

Prospective validation research is needed before these clinical predictors of pediatric PE can become guidelines.

Outcomes With Catheter-Directed vs Systemic Thrombolysis in Intermediate-Risk Pulmonary Emboli

Outcomes With Catheter-Directed vs Systemic Thrombolysis in Intermediate-Risk Pulmonary Emboli

A systematic review evaluated whether catheter-directed thrombolysis improved outcomes in patients with intermediate-risk pulmonary emboli.

Veno-Arterial Extracorporeal Membrane Oxygenation Effective for Massive PE

Veno-Arterial Extracorporeal Membrane Oxygenation Effective for Massive PE

The use of veno-arterial extracorporeal membrane oxygenation as bridge therapy for massive pulmonary embolism may allow clinicians to better triage patients to appropriate destination therapy.

HIV Viral Loads May Affect Echocardiographic Pulmonary Pressure

HIV Viral Loads May Affect Echocardiographic Pulmonary Pressure

Individuals who are HIV-positive may be at a higher risk for increased pulmonary pressure and mortality.

Anticoagulation Therapy Often Poorly Managed in Pulmonary Arterial Hypertension

Anticoagulation Therapy Often Poorly Managed in Pulmonary Arterial Hypertension

A study evaluated the quality of targeted anticoagulation in patients with PAH, and examined outcomes associated with poor time spent within targeted anticoagulation range.

Lung Transplantation for Pulmonary Arterial Hypertension: Overview and Bridging Therapies

Lung Transplantation for Pulmonary Arterial Hypertension: Overview and Bridging Therapies

Lung transplantation may be an option in patients with severe pulmonary arterial hypertension who do not respond well to medical therapy.

Riociguat Studied in Pediatric Patient With Pulmonary Arterial Hypertension

Riociguat Studied in Pediatric Patient With Pulmonary Arterial Hypertension

Select pediatric patients with pulmonary arterial hypertension may benefit from treatment with riociguat.

Clinical Challenge: 40-Year-Old Woman With Worsening Dyspnea on Exertion

Clinical Challenge: 40-Year-Old Woman With Worsening Dyspnea on Exertion

A 40-year-old woman presents with worsening shortness of breath after being treated with long-acting nifedipine for 2 years.

Improved Hemodynamics in CTEPH With Balloon Pulmonary Angioplasty

Improved Hemodynamics in CTEPH With Balloon Pulmonary Angioplasty

Hemodynamics may improve in patients with chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty with complication rates comparable to pulmonary endarterectomy.

Increasing 6-Minute Walking Distance in Peripheral Artery Disease

Increasing 6-Minute Walking Distance in Peripheral Artery Disease

Study results confirm the benefits of exercise vs granulocyte-macrophage colony-stimulating factor in improving 6-minute walk test in PAD.

Pulmonary Arterial Hypertension: Using Biomarkers to Assess Treatment Response

Pulmonary Arterial Hypertension: Using Biomarkers to Assess Treatment Response

Using biomarkers in pulmonary arterial hypertension may be a less invasive strategy for assessing response to treatment.

Thoracic and Pulmonary Conditions Associated With Connective Tissue Disease

Thoracic and Pulmonary Conditions Associated With Connective Tissue Disease

Pulmonary and thoracic symptoms often coincide with initial presentation of connective tissue disease.

Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: Definitions and Treatments

Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: Definitions and Treatments

Pulmonary arterial hypertension is becoming a major cause of death in patients with systemic sclerosis.

Idiopathic PAH vs Scleroderma-Associated PAH: Pulmonary Function and Hemodynamic Differences

Idiopathic PAH vs Scleroderma-Associated PAH: Pulmonary Function and Hemodynamic Differences

Results show statistically significant differences between SSc-PAH groups and iPAH groups for variables including age, sex, FVC capacity, total lung capacity, and FEV1, among others.

Impaired Cerebral Pressure-Flow Relationship in PAH

Impaired Cerebral Pressure-Flow Relationship in PAH

Patients with pulmonary arterial hypertension have reduced cerebrovascular reactivity to CO2.

Pulmonary Arterial Hypertension: Mechanisms of Exercise Intolerance

Pulmonary Arterial Hypertension: Mechanisms of Exercise Intolerance

Respiratory muscle dysfunction, iron deficiency, and skeletal muscle dysfunction have been implicated as mechanisms for exercise intolerance in pulmonary arterial hypertension.

Redesigned Inhalation Device for PAH Approved by FDA

Redesigned Inhalation Device for PAH Approved by FDA

The new device features a more ergonomic design with a single-button operation, an intuitive user interface to adjust breath counts, a rechargeable battery, and a display that guides patients through the inhalation process.

Phenotypes Associated With EIF2AK4 Mutations in PAH

Phenotypes Associated With EIF2AK4 Mutations in PAH

The frequency of eukaryotic translation initiation factor 2 alpha kinase 4 gene (EIF2AK4) mutations in patients with pulmonary arterial hypertension was investigated.

Pulmonary HTN Linked to Increased Mortality During Cardiac Catheterization

Pulmonary HTN Linked to Increased Mortality During Cardiac Catheterization

Borderline PH was linked to increased mortality after adjustment for 34 variables.

Pulmonary Edema After Prostacyclin Therapy for PAH Associated With Worse Outcomes

Pulmonary Edema After Prostacyclin Therapy for PAH Associated With Worse Outcomes

Patients who develop pulmonary edema after starting prostacyclin for pulmonary arterial hypertension have a greater risk for mortality.

PAH-Associated Congenital Heart Disease Outcomes Predicted by Pulmonary Artery Compliance

PAH-Associated Congenital Heart Disease Outcomes Predicted by Pulmonary Artery Compliance

Pulmonary vascular compliance may independently predict survival and prognosis in patients with pulmonary arterial hypertension associated with congenital heart disease.

Pulmonary Arterial Compliance Improved With Riociguat vs PDE5 Inhibitors

Pulmonary Arterial Compliance Improved With Riociguat vs PDE5 Inhibitors

Patients with pulmonary arterial hypertension experienced better improvements in pulmonary arterial compliance with riociguat compared with phosphodiesterase type 5 inhibitors.

Bronchoalveolar Lavage for Diagnosis of Idiopathic Pulmonary Fibrosis: Point/Counterpoint

Bronchoalveolar Lavage for Diagnosis of Idiopathic Pulmonary Fibrosis: Point/Counterpoint

Lung disease experts Athol Wells, MD, and Joshua Mooney, MD, MS, debate the diagnostic value of bronchoalveolar lavage in idiopathic pulmonary fibrosis.

Extent of Right Ventricular Epicardial Vascularization in Pulmonary Arterial Hypertension

Extent of Right Ventricular Epicardial Vascularization in Pulmonary Arterial Hypertension

Right ventricular epicardial vasculature is more extensive in patients with pulmonary arterial hypertension compared with individuals without disease.

No Associations Exist Between 6MWD and Maximum Oxygen Uptake in Pulmonary Arterial Hypertension

No Associations Exist Between 6MWD and Maximum Oxygen Uptake in Pulmonary Arterial Hypertension

Results indicate that further study of the relationship between the 6-minute walk distance test and functional capacity in PAH is necessary.

Association Between Pulmonary Hypertension and Hereditary Hemorrhagic Telangiectasia

Association Between Pulmonary Hypertension and Hereditary Hemorrhagic Telangiectasia

A study sought to describe the occurrence of different types of pulmonary hypertension in hereditary hemorrhagic telangiectasia.

Examining Anxiety, Depression Rates in CTEPH, PAH

Examining Anxiety, Depression Rates in CTEPH, PAH

Depression, anxiety, and reduced healthcare-related quality of life are common in patients with either pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.

Clinical Case: Patient With COPD and Worsening Dyspnea on Exertion

Clinical Case: Patient With COPD and Worsening Dyspnea on Exertion

A 65-year-old man with COPD presents with worsening exertional dyspnea.

Characteristics and Outcomes of Methamphetamine-Associated Pulmonary Arterial Hypertension

Characteristics and Outcomes of Methamphetamine-Associated Pulmonary Arterial Hypertension

Methamphetamine-associated pulmonary arterial hypertension has a higher risk for clinical worsening compared with idiopathic pulmonary arterial hypertension.

Pulmonary Veno-Occlusive Disease Affects Survival in PAH/Systemic Sclerosis

Pulmonary Veno-Occlusive Disease Affects Survival in PAH/Systemic Sclerosis

Having at least 2 features of pulmonary veno-occlusive disease demonstrated a trend toward worse survival in patients with pulmonary arterial hypertension and systemic sclerosis.

Guidelines Needed for 6-Minute Walk Test in Idiopathic Pulmonary Fibrosis

Guidelines Needed for 6-Minute Walk Test in Idiopathic Pulmonary Fibrosis

Specific guidelines should be developed for the use of the 6-minute walk test in idiopathic pulmonary fibrosis.

Pulmonary Arterial Hypertension: Future Treatment May Depend on Race and Ethnicity

Pulmonary Arterial Hypertension: Future Treatment May Depend on Race and Ethnicity

Pulmonary arterial hypertension tends to vary in presentation in patients of different races and ethnicities.

Right Ventricular Morphology Predictive of Pulmonary Hypertension Type

Right Ventricular Morphology Predictive of Pulmonary Hypertension Type

Differences in right ventricular morphology may predict the hemodynamic nature of pulmonary hypertension.

Pulmonary Endarterectomy in Chronic Thromboembolic Pulmonary Hypertension

Pulmonary Endarterectomy in Chronic Thromboembolic Pulmonary Hypertension

Pulmonary endarterectomy is an effective and durable treatment for chronic thromboembolic pulmonary hypertension.

Managing Pulmonary Hypertension in Preterm Neonates: Updates in an Emerging Field

Managing Pulmonary Hypertension in Preterm Neonates: Updates in an Emerging Field

Prenatal factors such as intrauterine growth retardation, infection, and placental inflammation can affect lung development in neonates.

No Increased Risk for VTE After Flu Vaccine in People Older Than 50

No Increased Risk for VTE After Flu Vaccine in People Older Than 50

Influenza vaccination does not increase the risk for venous thromboembolism in patients older than 50 years of age.

No Difference in Short-Term Outcome Between Saddle and Nonsaddle Pulmonary Embolism

No Difference in Short-Term Outcome Between Saddle and Nonsaddle Pulmonary Embolism

Similar short-term outcomes were seen in patients with saddle and nonsaddle pulmonary embolism.

Survival Rates in Eisenmenger Syndrome Treated With Pulmonary Vasodilator Therapy

Survival Rates in Eisenmenger Syndrome Treated With Pulmonary Vasodilator Therapy

Patients undergoing pulmonary vasodilatory therapy were more functional at initial presentation.

Poorer Right Atrial Function Predicts Worse Prognosis in Pulmonary Arterial Hypertension

Poorer Right Atrial Function Predicts Worse Prognosis in Pulmonary Arterial Hypertension

Poor outcomes in pulmonary arterial hypertension may be linked to worsening right atrial function.

Prediction of Short-, Long-Term Mortality in Elderly With Stable Acute PE

Prediction of Short-, Long-Term Mortality in Elderly With Stable Acute PE

Charleston comorbidity index is an independent predictor of mortality in patients with hemodynamically stable pulmonary embolism.

Page 1 of 2

Sign Up for Free e-newsletters